These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 9044845)
1. Development of a severe combined immunodeficiency (SCID) mouse model consisting of highly disseminated human B-cell leukemia/lymphoma, cure of the tumors by systemic administration of immunotoxin, and development/application of a clonotype-specific polymerase chain reaction-based assay. Yoshida M; Rybak RJ; Choi Y; Greenberg SJ; Barcos M; Kawata A; Matsuno F; Tsai H; Seon BK Cancer Res; 1997 Feb; 57(4):678-85. PubMed ID: 9044845 [TBL] [Abstract][Full Text] [Related]
2. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody. Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098 [TBL] [Abstract][Full Text] [Related]
3. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7. Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092 [TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites. Ghetie MA; Richardson J; Tucker T; Jones D; Uhr JW; Vitetta ES Cancer Res; 1991 Nov; 51(21):5876-80. PubMed ID: 1933855 [TBL] [Abstract][Full Text] [Related]
5. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284 [TBL] [Abstract][Full Text] [Related]
6. Efficient transplantation of human non-T-leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibodies SN5 and SN6. Hara H; Luo Y; Haruta Y; Seon BK Cancer Res; 1988 Aug; 48(16):4673-80. PubMed ID: 2969282 [TBL] [Abstract][Full Text] [Related]
7. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency. Gunther R; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Uckun FM Leukemia; 1993 Feb; 7(2):298-309. PubMed ID: 7678882 [TBL] [Abstract][Full Text] [Related]
8. Antidisialoganglioside ricin A-chain immunotoxins show potent antitumor effects in vitro and in a disseminated human neuroblastoma severe combined immunodeficiency mouse model. Gottstein C; Schön G; Tawadros S; Kube D; Wargalla-Plate UC; Hansmann ML; Wacker HH; Berthold F; Diehl V; Engert A Cancer Res; 1994 Dec; 54(23):6186-93. PubMed ID: 7954465 [TBL] [Abstract][Full Text] [Related]
9. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide. Jansen B; Kersey JH; Jaszcz WB; Gunther R; Nguyen DP; Chelstrom LM; Tuel-Ahlgren L; Uckun FM Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881 [TBL] [Abstract][Full Text] [Related]
10. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies. Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of an anti-CD7-ricin A chain immunoconjugate in a novel murine model of human T-cell leukemia. Fishwild DM; Aberle S; Bernhard SL; Kung AH Cancer Res; 1992 Jun; 52(11):3056-62. PubMed ID: 1375534 [TBL] [Abstract][Full Text] [Related]
13. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Seon BK; Matsuno F; Haruta Y; Kondo M; Barcos M Clin Cancer Res; 1997 Jul; 3(7):1031-44. PubMed ID: 9815781 [TBL] [Abstract][Full Text] [Related]
14. Synergistic potentiation of in vivo antitumor activity of anti-human T-leukemia immunotoxins by recombinant alpha-interferon and daunorubicin. Yokota S; Hara H; Luo Y; Seon BK Cancer Res; 1990 Jan; 50(1):32-7. PubMed ID: 2293557 [TBL] [Abstract][Full Text] [Related]
15. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice. de Kroon JF; de Paus RA; Kluin-Nelemans HC; Kluin PM; van Bergen CA; Munro AJ; Hale G; Willemze R; Falkenburg JH Exp Hematol; 1996 Jul; 24(8):919-26. PubMed ID: 8690051 [TBL] [Abstract][Full Text] [Related]
16. Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice. Flavell DJ; Warnes SL; Noss AL; Flavell SU Br J Cancer; 2000 Dec; 83(12):1755-61. PubMed ID: 11104577 [TBL] [Abstract][Full Text] [Related]
17. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin. Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056 [TBL] [Abstract][Full Text] [Related]
18. An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins. Tazzari PL; de Totero D; Bolognesi A; Testoni N; Pileri S; Roncella S; Reato G; Stein H; Gobbi M; Stirpe F Haematologica; 1999 Nov; 84(11):988-95. PubMed ID: 10553158 [TBL] [Abstract][Full Text] [Related]
19. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain. Fulton RJ; Uhr JW; Vitetta ES Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547 [TBL] [Abstract][Full Text] [Related]
20. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model]. Wang YD; Hu Y; Zhang L; Huang J; Sun CY Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]